VK2735 makes Viking Therapeutics an attractive buyout candidate or big pharma partner. Its oral formulation reported good ...

Viking Therapeutics is primed for acquisition due to its robust pipeline and potential as a market disruptor. Find out why ...

Key Insights Significantly high institutional ownership implies Viking Therapeutics' stock price is sensitive to ...

In terms of liquidity and interest, the mean open interest for Viking Therapeutics options trades today is 783.0 with a total ...

Viking Therapeutics (NASDAQ: VKTX) has emerged as a beacon of hope in an otherwise lackluster year for healthcare stocks. The ...

The pre-revenue biotech's Q1 numbers show that it's in financially solid shape, though it has a long way to go before it could bring a drug to market.

Q1 2024 Earnings Call Transcript April 24, 2024 Viking Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.26 ...

With a volume of 712,447, the price of VKTX is up 0.74% at $75.97. RSI indicators hint that the underlying stock may be ...

In this match-up, Pfizer arguably stands out as the more attractive investment. The company's stock is less risky, offers a ...

Brian Lian; President, Chief Executive Officer, Director; Viking Therapeutics Inc Greg Zante; Chief Financial Officer; Viking Therapeutics Inc Joon Lee; Analyst; Truist Securities, Inc. Annabel ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Investors are well aware of the explosive growth potential in weight loss drug ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Investing in Russell 2000 stocks is a smart idea because it ...